Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00956020 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation
A Phase 1 study, sponsored by The New York Eye & Ear Infirmary.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00956020 is a Phase 1 study that has completed, run by The New York Eye & Ear Infirmary. The registered enrollment target is 4 participants.
The verdict
NCT00956020, a Phase 1 study, has completed, sponsored by The New York Eye & Ear Infirmary.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Autologous platelet rich fibrin matrix will release growth factors which could increase the production of dermal proteins or affect the vascularity and status of neighboring tissues. This study is designed to evaluate the histologic and biochemical effect of injection of platelet rich fibrin matrix into the skin.
Interventions
- BIOLOGICAL Platelet rich fibrin matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00956020
The ClinicalTrials.gov registry entry for NCT00956020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye & Ear Infirmary, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Platelet rich fibrin matrix is the first listed.
NCT00956020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00956020 about?
NCT00956020 is a clinical study titled "Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation". Autologous platelet rich fibrin matrix will release growth factors which could increase the production of dermal proteins or affect the vascularity and status of neighboring tissues. This study is designed to evaluate the histologic and biochemical effect of injection of platelet rich fibrin matrix ...
What is the current status of trial NCT00956020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00956020?
The interventions under investigation include: Platelet rich fibrin matrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00956020?
This trial is sponsored by The New York Eye & Ear Infirmary, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.